In the middle of the summer Abera Bioscience pulled off a capitalization on their own, largely supported by existing investors. The money will finance GMP manufacturing and a Phase I study of Aberas nasal, pneumococcal vaccine. Through Abera we contacted the lead investor Gunnar Sachs for a short interview. [sponsored article]
Håll dig uppdaterad med det senaste inom nyemissioner